Prior Authorization of Provenge (sipuleucel-T) - Pharmacy Service
Customize your policy alerts
Sign up for all Pennsylvania Insurance Department policy alerts
Know when Pennsylvania Insurance Department releases new policies or updates existing guidance.
Monitor payer policy activity
Requires prior authorization for all Provenge (sipuleucel-T) prescriptions under Pennsylvania Medical Assistance fee-for-service and describes the clinical documentation and dose/duration limits used to determine medical necessity for covered recipients.
The Department will require prior authorization of prescriptions for Provenge (sipuleucel-T).
Prior authorization clinical review guidelines and limits on dose and duration of therapy for Provenge (sipuleucel-T) are included in updated provider handbook pages.
Coverage and Medical Necessity Criteria
Initial therapy / Medical necessity criteria
Covered when ALL of the following are met unless overridden by physician reviewer judgment
If the recipient does not meet these criteria, a physician reviewer may still approve the request based on professional judgment.
Recipients with documented hepatic metastases are excluded from approval for Provenge (sipuleucel-T). This exclusion is one of the required criteria in Section B and must be absent for a prior authorization to be approved.
Prior authorization staff will first apply the clinical guidelines in Section B. If the request does not meet those guidelines, it will be referred to a physician reviewer for a medical necessity determination; the physician reviewer may determine the request is not medically necessary if sufficient justification is not found, or may approve based on professional judgment.
Initial Prior Authorization Requirements
Initial therapy
Initial prior authorization requires meeting the clinical criteria listed in Section B
Physician reviewer may approve exceptions based on professional judgment.
Key Clinical Values and Definitions
Dose and Quantity Limits
Provider Requirements, Prior Authorization, and Denials
Prior authorization required
All prescriptions for Provenge (sipuleucel-T) must receive prior authorization; requests are reviewed against the provider handbook clinical guidelines to determine medical necessity.
Dose and duration limit
Approval is limited to one course of therapy consisting of three doses administered at approximately two-week intervals.
- One course = 3 doses given at approximately 2-week intervals
Follow handbook PA procedures and submit required documentation
Providers must follow the procedures in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook and submit documentation addressing the clinical review guidelines included in the provider handbook (SECTION II) when requesting prior authorization.
- Documentation should address the clinical elements specified in SECTION II (e.g., prescriber specialty, diagnosis, testosterone level, ECOG status, life expectancy, hepatic metastases, concurrent therapies)
Denial risk for unmet guidelines
Requests that do not meet the clinical guidelines in Section B will be referred to a physician reviewer for a medical necessity determination and may be denied if the reviewer does not find sufficient justification.
- Prior authorization personnel apply Section B clinical guidelines; failures are escalated to a physician reviewer
- A physician reviewer may approve only when, in professional judgment, the services are medically necessary
Background and Rationale
Provenge (sipuleucel-T) is an autologous cellular immunotherapy used in specified prostate cancer indications. The DUR Board reviewed utilization and recommended requiring prior authorization with defined clinical criteria and limits to ensure appropriate use and alignment with evidence and compendia; these criteria include prescriber specialty, indication per FDA label or nationally recognized compendia, testosterone <50 ng/dL (unless bilateral orchiectomy), ECOG performance status 0-1, life expectancy >6 months, absence of hepatic metastases, and avoidance of concurrent chemotherapy or immunosuppressive agents.
Policy Changes and Effective Dates
Department implemented prior authorization requirement and issued updated provider handbook pages with clinical review guidelines and dose/duration limits for Provenge (sipuleucel-T).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.